American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
May 12, 2023
Earnings Call Speaker Segments
Stephanie Prince
executiveThanks, Anthony, and I appreciate all of you being with us today. This morning, prior to the market opening, AMS released its earnings press release for the first quarter of 2023. Should you require a copy, you'll find it on the company's Web site, ashs.com, listed under Press Releases within the Investors tab. Prior to handing the call to management, I'd like to make the following comments regarding forward-looking statements. Kindly be aware that a number of remarks that might be provided during this conference call concerning the company's future expectations, plans and prospects are forward-looking statements for the purposes of safe harbor provisions under the Private Securities Litigation Reform 1995. As a consequence of various important factors, including those addressed in the company's filings with the SEC, actual results may differ materially from those suggested by these forward-looking statements. This encompasses the company's annual report on Form 10-K for the year ended December 31, 2022 along with the definitive proxy statement for the Annual Meeting of Shareholders scheduled to take place on June 20, 2023. No obligation is assumed by the company to update the information contained in this conference call. At this point, I'd like to hand the call over to Ray Stachowiak, Executive Chairman of AMS. Ray?
Ray Stachowiak
executiveThank you, Stephanie, and good morning to all of you. We appreciate your participation today in our earnings conference call for the first quarter of 2023. I'll start things off with a few opening comments, and after that I'll hand things over to Peter Gaccione, who was recently named Chief Executive Officer of American Shared. Bob Hiatt, who has just taken on the role of Chief Financial Officer, will follow with a review of the financials for our first quarter results. Once those prepared remarks are finished, we'll take your questions. Today I want to kick things off by talking about how our team has grown over the last 12 months. To my way of thinking, these represent some of the last pieces that need to fall into place in the turnaround we've been carrying out at AMS over the past couple of years. Most recently, Bob Hiatt came aboard as our Chief Financial Officer in April. Bob brings deep financial experience, having held the CFO position at companies both public and private. My belief is that he'll contribute substantially to our growth; over the past 12 months, we've also brought in our new CEO, Peter Gaccione, who is a highly regarded executive within our industry; we also brought on Tim Keel as Vice President of Domestic Sales and Business Development, along with Ranjit Pradham as our new in-house Customer Advocate. His responsibility is expanding the relationships we currently have with clients. Ernie Bates keeps thriving in pursuing our international opportunities, continuing as Vice President of International Sales and Business Development. Craig Tagawa, who serves as our President, keeps delivering extremely valuable input when it comes to structuring and negotiating the orders we'll place down the road. Although these investments have raised our expenses for the time being, our view is that every one of them was required to grow revenue in the future; these investments have started to bear fruit, with our sales pipeline now filled with many possibilities making their way through the complicated sales cycle that our product offerings demand. In the first quarter, we obtained the approvals we had been awaiting to install the upgraded Gamma Knife ICON in Ecuador, plus the approval for the new linear accelerator, or LINAC, for our new cancer center joint venture in Puebla, Mexico. Installation of this new LINAC is already underway, and we're excited about the anticipated start-up of both systems in the third quarter of this year. We kept generating strong positive cash flow in the first quarter in spite of its challenges; we finished the quarter holding $13.2 million in cash, which works out to roughly $2.03 per share. If we take that $2.03 away from our recent stock price of $2.80 a share, it certainly appears to me that this dramatically undervalues all our other tangible assets. Going forward, with stronger international growth ahead, the many new contract possibilities here at home and a solid financial position, we have confidence that AMS is ready for new growth. I'll now hand the call over to Peter.
Peter Gaccione
executiveThanks, Ray, and good morning to all of you. Our sales and customer support teams have stayed quite busy since the conference call we last held. On the international side, we've put substantial effort into Peru and Ecuador, aiming to boost education and marketing efforts directed at the physicians who refer patients to us; our network there is sizable, and by growing our customer support teams, we've strengthened communication with all of them. Part of that involves letting every referring physician know that new Gamma Knife systems are being installed at our facilities in the very near future; patients will gain several added treatment capabilities from these systems, among them shorter treatment durations, frameless procedures, sophisticated onboard CT imaging that allows imaging and treatment on the same day, plus the ability to plan and approve treatment remotely. The patient treatment experience will be better because of all these changes, departmental workflow will rise, and so will the crucial relationship we maintain with our physician referral network. In Ecuador, as Ray noted, the permits we needed have now come through, letting us upgrade the existing Gamma Knife 4C to the Gamma Knife ICON, with delivery and installation slated for July, August 2023. At Puebla, Mexico, we're also where we should be. The new LINAC featuring VMAT image-guided radiation and radiosurgery arrived at the site last week, and mechanical equipment installation has already started, just as planned. We're eager for the third quarter, when both advanced systems will start up. Here in the US, the Customer Advocate we appointed recently has been working hard alongside many of our sites to figure out ways to grow patient volumes; our belief is that the answer lies in combining more marketing with potential equipment upgrades that introduce new treatment capabilities at certain sites, which likewise means our agreements get extended; that's exactly what our second order this year is, as Ray mentioned, a five year agreement extension paired with an equipment upgrade to the newest Gamma Knife Esprit. Patients will receive additional treatment capabilities from the Esprit that enhance the patient treatment experience, such as shorter treatment durations, and we anticipate patient volume growing because of it. Once installed in the fourth quarter, it will be the first Esprits in the US. Beyond that, our first order this year remains scheduled to start installation in September 2023, as planned. Overall, sales activity is quite robust, with numerous projects progressing through our sales pipeline; the two orders we've already announced this year are part of that. Gamma Knife projects around the world are included in this activity, as are US projects involving MR/LINACs and proton beam radiation therapy centers. Furthermore, with US market trends indicating greater consolidation of cancer centers, American Shared is getting more engaged in talks regarding US cancer center acquisitions, joint ventures and other inventive turnkey financial models, much like certain successes we've had before. Confidentiality agreements prevent us from sharing anything further, but the key point is that these projects are new and additional, recently added to a sales funnel that was already growing. Our presence across the 4 main platforms has grown substantially as well, and my sense is that this boost in marketing, together with wider exposure of the distinctive value proposition American Shared offers, accounts for much of the interest we're seeing. Let me remind everyone that American Shared's distinctive standing gives clinical cancer treatment centers a way to work with every leading original equipment manufacturer via a single turnkey vendor inside one inventive relationship. Multiple avenues for growth are now open to American Shared. And thanks to our recently enlarged team and substantial financial capacity, we plan to take an active role in a great number of them. At this point I'll hand the call to Bob, who will walk through the financials.
Bob Hiatt
executiveThank you, Peter, and good morning to all of you. Revenue for the first quarter rose 1.6% to $4.9 million, up from $4.8 million during the same period a year earlier. In Florida, first quarter revenue from the proton therapy system grew 13.5% to $2.3 million versus $2.0 million, largely because average reimbursement was higher period-over-period in the current quarter. Proton therapy fractions totaled 1,536 in the first quarter, which represents a 5.7% decrease, or 92 fractions, from 1,628 in last year's first quarter. Gamma Knife revenue overall fell 7% to $2.6 million, compared with $2.8 million in the first quarter of last year. Domestic Gamma Knife revenue dropped 8.9% to $1.9 million, while international revenue declined 1.4% to $0.7 million period-over-period. The overall Gamma Knife revenue decline stemmed from fewer procedures, partly offset by higher average reimbursement. That rise in average reimbursement is still being driven by a favorable shift in payer mix toward more commercial payers. Total Gamma Knife procedures fell by 10.9% to 293 in the first quarter of 2023, down from 329 in the first quarter of 2022, which also falls within the range of normal cyclical fluctuations. Domestic Gamma Knife procedures decreased 15% to 216, and international procedures rose 2.7% to 77 for the first quarter of 2023 compared to 2022. As Peter mentioned, our new Customer Advocate has been working to boost customer utilization. And we anticipate additional international growth now that approvals are in place for the ICON upgrade with advanced treatment capabilities at our Gamma Knife Cancer Center in Ecuador, and for the new linear accelerator, or LINAC, for our new cancer center joint venture in Puebla, Mexico. Both are expected to be in place and treating patients in the third quarter of this year. Gross margin for the first quarter declined 7.7% to $1.9 million, or 38.7% of revenue, compared to gross margin of $2.1 million, or 42.6% of revenue, for the first quarter of 2022. Selling and administrative costs rose by 16.7% to $1.5 million for the first quarter compared to $1.3 million, as we continue to invest in sales and marketing initiatives tied to new business opportunities. Net interest expense grew by $184,000 in the 2023 period compared to $148,000 last year, an increase of 24.3%, driven by higher interest rates on the company's variable rate debt. Operating income was $98,000, compared to operating income of $600,000 in the first quarter of 2022, a decrease of 83.7%, which reflects higher operating costs and selling and administrative expenses. Income tax expense fell 67% to $68,000 for the first quarter of 2023, compared to $206,000 for the first quarter last year. The period-over-period decrease was primarily due to lower earnings in the current period and return-to-provision adjustments arising from foreign tax returns, as well as permanent domestic tax differences in the prior year. For American Shared Hospital Services, net income attributable to the company during 2023's first quarter came to $188,000, which works out to $0.03 per diluted share. That compares with net income of $269,000, or $0.04 per diluted share, in the same quarter of 2022. The drop stemmed mainly from increased interest expense along with the greater selling and administrative expenses I mentioned earlier. Weighted average common shares outstanding on a fully diluted basis totaled 6,472,000 for the first quarter of 2023 and 6,299,000 for the first quarter of 2022. Adjusted EBITDA, which is a non-GAAP financial measure, came in at roughly $1.9 million in each of those periods. As of March 31, 2023, cash, cash equivalents and restricted cash stood at $13.2 million, which represents a $748,000 increase from December 31, 2022. Shareholders' equity, excluding noncontrolling interest in subsidiaries, reached $21.9 million, or $3.54 per outstanding share, when the quarter ended, versus $21.6 million, or $3.50 per outstanding share, at March 31, 2022. That brings the formal portion of our presentation to a close. We appreciate your joining us today. We're eager to share updates on our progress in the quarters ahead.
Ray Stachowiak
executiveAnthony, thanks, and I appreciate all of you taking the time to be with us. I want to offer a few quick thoughts. First, take a look at our balance sheet, and you'll see that the cash we hold right now exceeds our interest-bearing debt — that's something of a milestone. And above all, we've put together an outstanding team. Our management group is well-positioned and brings deep experience, ready to expand this company and achieve our objectives of lasting growth along with profitability. AMS stands in its strongest position in several years. It feels as though every element is now where it needs to be, and our excitement about what lies ahead is high. We can't wait to talk with you once more during our second quarter call in mid-August. If anything comes up before that, reach out to us directly. Take care, stay safe. Goodbye.
Operator
operatorThat brings us to the end of this call. We appreciate everyone joining the presentation today. You're free to log off at this point.
For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.